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Abstract
Treating to a target of clinical remission or low disease activity is an important principle for managing rheumatoid arthritis 
(RA). Despite the availability of biologic disease-modifying antirheumatic drugs (bDMARDs), a substantial proportion 
of patients with RA do not achieve these treatment targets. Upadacitinib is a once-daily, oral Janus kinase (JAK) inhibitor 
with increased selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2. The SELECT phase III upadacitinib clini-
cal program comprised five pivotal trials of approximately 4400 patients with RA, including inadequate responders (IR) 
to conventional synthetic (cs)DMARDs or bDMARDs. This review aims to provide insights into the benefit–risk profile 
of upadacitinib in patients with RA. Upadacitinib 15 mg once daily, in combination with csDMARDs or as monotherapy, 
achieved all primary and ranked secondary endpoints in the five pivotal trials across csDMARD-naïve, csDMARD-IR, and 
bDMARD-IR populations. Upadacitinib 15 mg also demonstrated significantly higher rates of remission and low disease 
activity in all five pivotal trials, compared with placebo, methotrexate, or adalimumab. Labeled warnings of JAK inhibitors 
include serious infections, herpes zoster, malignancies, major cardiovascular events, and venous thromboembolic events. 
Short- and long-term integrated analyses showed that upadacitinib 15 mg was associated with increased risk of herpes zoster 
and creatine phosphokinase elevations compared with methotrexate and adalimumab but otherwise had comparable safety 
with these active comparators. This review suggests that upadacitinib 15 mg had a favorable benefit–risk profile. The safety 
of upadacitinib will continue to be monitored in long-term extensions and post-marketing studies.
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Key Points 
Upadacitinib is an oral Janus kinase inhibitor that dem-
onstrates a favorable benefit–risk profile in patients with 
moderately to severely active rheumatoid arthritis at a 
dose of 15 mg once daily.
Upadacitinib-related benefits include durable efficacy, 
including achievement of remission and low disease 
activity, improved physical function, and prevention of 
structural joint damage.
Labeled warnings of upadacitinib include serious infec-
tions, herpes zoster, malignancies, major cardiovascular 
events, and venous thromboembolic events, and upa-
dacitinib was associated with increased rates of herpes 
zoster and creatine phosphokinase elevations compared 
with methotrexate and adalimumab based on integrated 
clinical data.
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1  Unmet Needs in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflamma-
tory autoimmune disease that causes significant pain, dis-
ability, and progressive joint destruction. Over time, without 
adequate treatment, irreversible joint destruction and loss of 
function can lead to significant disability and impaired qual-
ity of life (QoL) [1, 2]. The prevalence of RA ranges from 
3.1 to 10.7 per 1000 in Europe, the USA, and Japan [3, 4], 
and up to 60–69% of patients with RA manifest moderately 
to severely active disease [5].
Conventional synthetic disease-modifying antirheumatic 
drugs (csDMARDs) such as methotrexate with or without 
short-term corticosteroids are the first-line treatment for 
RA [6, 7]. For patients who become inadequate respond-
ers (IRs) to csDMARDs or experience csDMARD toxici-
ties [8], treatment with biologic DMARDs (bDMARDs) or 
targeted synthetic DMARDs (tsDMARDs) in combination 
with a csDMARD or as monotherapy is recommended [6, 
7, 9]. Every patient with RA should be treated to the targets 
of clinical remission or low disease activity (LDA) [6, 10]. 
However, approximately half of patients in the real world 
do not achieve remission or LDA after 12 months of treat-
ment [11].
Use of bDMARDs including inhibitors of tumor necrosis 
factor (TNF), interleukin-6 receptors, and T/B-cell activity 
provides significant improvements in efficacy when com-
pared with csDMARDs alone, including greater inhibition 
of radiographic progression [12, 13]. However, these drugs 
must be administered subcutaneously or intravenously and 
are recommended for use with methotrexate to optimize 
outcomes, in part by reducing the development of antid-
rug antibodies (i.e., immunogenicity) [14]. Up to 40% of 
patients treated with a bDMARD do not achieve a 20% 
improvement in American College of Rheumatology (ACR) 
criteria (ACR20; primary failure), with most patients also 
not achieving treatment targets such as clinical remission 
or LDA. Further, patients who initially respond to therapy 
may lose response over time (secondary failure) or experi-
ence adverse events (AEs) [15]. This suggests that, despite 
the availability of bDMARDs, there is still an unmet need 
for effective RA management.
2  Janus Kinase Inhibitors 
for the Management of Rheumatoid 
Arthritis
Inhibition of Janus kinase (JAK) with small-molecule inhibi-
tors (i.e., tsDMARDs) has been shown to be an effective 
mechanism for the treatment of RA based on data from mul-
tiple randomized controlled trials of JAK inhibitors across 
csDMARD-naïve, csDMARD-IR, and bDMARD-IR patient 
populations [16–19]. Three JAK inhibitors have received 
regulatory approval for use in treating RA in the EU, the 
USA, and other countries worldwide: tofacitinib, baricitinib, 
and upadacitinib. Filgotinib is approved in the EU for the 
treatment of RA, but it has not received approval (at the time 
of writing) from the USA, whose regulatory authorities have 
requested additional data [19, 20]. Additionally, peficitinib 
is approved in Japan, South Korea, and Taiwan for the treat-
ment of RA.
It has been hypothesized that JAK inhibitors, by target-
ing multiple cytokines involved in RA pathogenesis, could 
provide superior efficacy to bDMARDs that target single 
pathways [21], and the efficacy of JAK inhibitors versus 
bDMARDs has been assessed in several head-to-head stud-
ies. In ORAL STRATEGY, tofacitinib 5 mg twice daily 
(BID) + weekly methotrexate was shown to be non-inferior 
but not superior to adalimumab + methotrexate at month 6 
based on 50% improvement in ACR criteria (ACR50) [22]. 
In RA-BEAM, baricitinib 4 mg once daily + methotrexate 
was superior to adalimumab 40 mg every other week (EOW) 
+ methotrexate at week 12 based on ACR20 response and 
improvement in Disease Activity Score of 28 joints with 
C-reactive protein (DAS28[CRP]) but was not significantly 
different to adalimumab + methotrexate for more stringent 
outcomes such as DAS28(CRP) < 2.6 or remission deter-
mined by either Clinical Disease Activity Index (CDAI) < 
2.8 or EULAR/ACR Boolean criteria [23, 24]. Baricitinib 
2 mg once daily (the recommended dose in the USA and 
in certain populations in the EU and Japan) has not been 
compared with adalimumab [17]. Upadacitinib 15 mg once 
daily + methotrexate has demonstrated superiority over adal-
imumab + methotrexate based on ACR50 and improvement 
in both pain and physical function, as well as significantly 
higher DAS28(CRP) < 2.6 response rates and remission 
rates determined by CDAI < 2.8 and EULAR/ACR Boolean 
criteria than adalimumab + methotrexate at week 12 [25]. 
Filgotinib 200 mg once daily + methotrexate demonstrated 
non-inferiority based on DAS28(CRP) ≤ 3.2 and higher 
DAS28(CRP) < 2.6 response rates compared with adali-
mumab + methotrexate at week 12 [19, 26].
Similar to bDMARDs, JAK inhibitors, including tofaci-
tinib 5 mg or 10 mg BID as monotherapy [27], baricitinib 4 
mg once daily + methotrexate [17, 28], upadacitinib 15 mg 
once daily either with methotrexate or as monotherapy [18, 
25, 29], and filgotinib 200 mg once daily either with metho-
trexate or as monotherapy [19, 26, 30, 31], demonstrated 
significant inhibition of structural progression compared 
with placebo and/or methotrexate. Unlike the majority of 
bDMARDs, all of the approved JAK inhibitors are indi-
cated for use either as monotherapy or in combination with 
methotrexate [16–19]. JAK inhibitors have other potential 
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advantages over bDMARDs, including oral administration, 
no immunogenicity, and a shorter half-life than bDMARDs.
Long-term safety evaluations are ongoing to assess 
potential latency events of JAK inhibitors such as malig-
nancies and major adverse cardiovascular events (MACE). 
Safety signals emerging from phase III studies and limited 
observational real-world evidence of JAK inhibitors include 
infections, comprising serious and opportunistic infections 
and, notably, an increased incidence of herpes zoster [32]. 
A post-marketing study reported an increased risk of seri-
ous infection with fatal outcome associated with tofacitinib 
5 mg BID; this has led to label restrictions in EU countries 
for patients aged > 65 years [16, 33]. Changes in labora-
tory parameters (e.g., creatine phosphokinase [CPK]) have 
also been observed in JAK inhibitor studies, and dose reduc-
tions are required in patients with moderate or severe renal 
impairment for tofacitinib, baricitinib, and filgotinib [16, 17, 
19, 32]. A potential risk of venous thromboembolic events 
(VTEs), including pulmonary embolism (PE) and deep vein 
thrombosis (DVT), has also been identified from phase III 
clinical trials (baricitinib) and has been observed in the post-
marketing setting (tofacitinib) [33, 34].
3  Upadacitinib
In this benefit–risk report, we focus on upadacitinib, an oral 
JAK inhibitor with preferential activity toward JAK1 over 
JAK2, JAK3, and tyrosine kinase 2 [35, 36]. Upadacitinib 15 
mg once daily has been approved for the treatment of mod-
erately to severely active RA in adults who are IRs or have 
an intolerance to methotrexate, either as monotherapy or 
in combination with methotrexate or other non-bDMARDs, 
depending on local labeling [18, 37]. A dose of 7.5 mg once 
daily is also approved in Japan.
3.1  Upadacitinib Phase III Clinical Program 
for Rheumatoid Arthritis
The SELECT phase III clinical development program evalu-
ated the efficacy and safety of upadacitinib with background 
csDMARDs in both csDMARD-IR and bDMARD-IR 
patient populations and as a monotherapy in patients who 
were naïve to methotrexate or methotrexate-IR across five 
pivotal randomized, multicenter, double-blind, parallel-
group, placebo or active comparator-controlled studies 
(Table 1 in the Electronic Supplementary Material [ESM]). 
Two additional studies were included in the SELECT pro-
gram: SELECT-CHOICE, which evaluated the safety and 
efficacy of upadacitinib versus abatacept in bDMARD-IR 
patients [38], and SELECT-SUNRISE, which evaluated upa-
dacitinib in Japanese patients [39]. Each phase III study had 
separate primary endpoints to meet different requirements 
from the European Medicines Agency (EMA), the US Food 
and Drug Administration (FDA), and the Japan Pharmaceu-
ticals and Medical Devices Agency (Table 1). Further details 
of study-specific assessments are outlined in the ESM.
3.1.1  Efficacy Assessments
Efficacy outcomes assessed across studies included signs 
and symptoms of RA (ACR response rates and change from 
baseline in DAS28[CRP]), remission and LDA rates, physi-
cal function (Health Assessment Questionnaire-Disability 
Index [HAQ-DI]) [40, 41], and patient-reported outcomes, 
including pain and fatigue. Radiographic progression, as 
assessed by the van der Heijde modified Total Sharp Score 
(mTSS) [42], was included in two studies: SELECT-EARLY 
(methotrexate-naïve patients) and SELECT-COMPARE 
(methotrexate-IR patients).
3.1.2  Safety Assessments
AEs, physical examinations, vital signs, electrocardiograms, 
and laboratory tests were collected and assessed as previ-
ously described [43]. In brief, AEs were identified using 
the standardized Medical Dictionary for Regulatory Activi-
ties (MedDRA) query or company MedDRA query search 
criteria. Treatment-emergent AEs (TEAEs: AE onset on or 
after the first dose and ≤ 30 days after the last dose of pla-
cebo, methotrexate, or upadacitinib, or ≤ 70 days after the 
last dose of adalimumab) were summarized. AEs of special 
interest included AEs with increased prevalence in patients 
with RA and labeled or emerging risks for immunomodula-
tors and/or other JAK inhibitors. All potential cardiovascu-
lar events, including thromboembolic events, were blindly 
adjudicated by an independent cardiovascular adjudication 
committee. MACE included cardiovascular death, non-fatal 
myocardial infarction, and non-fatal stroke. VTEs included 
DVT and PE.
4  Methodology
This study reports the benefits and risks of upadacitinib 15 
mg once daily (the approved dose for RA in the USA and the 
EU) as monotherapy and in combination with csDMARDs, 
compared with placebo, methotrexate, and adalimumab, 
based on pooled data from five pivotal upadacitinib phase 
III clinical trials (SELECT-BEYOND, SELECT-COM-
PARE, SELECT-NEXT, SELECT-MONOTHERAPY, and 
SELECT-EARLY). Selected benefits and risks of upadaci-
tinib (Sect. 4.1) were assessed up to the time of regulatory 
submission (Sect. 4.2) and the long-term integrated safety 
profile of upadacitinib (Sect. 4.3) was reviewed as a supple-
ment to the benefit–risk analysis.
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4.1  Assessed Benefits and Risks
Efficacy outcomes analyzed to assess the benefits of upa-
dacitinib were ACR20/50/70, achievement of LDA, and 
remission defined by CDAI ≤ 10 or ≤ 2.8, respectively, 
DAS28(CRP) < 2.6 or ≤ 3.2, and minimal clinically impor-
tant difference (MCID) in HAQ-DI (reduction from baseline 
≥ 0.22) [40, 41]. These represent either primary endpoints 
of the upadacitinib phase III studies or secondary endpoints 
commonly recognized by regulatory authorities (US FDA 
and/or EMA) to demonstrate efficacy in RA required for 
drug approval. Radiographic and patient-reported outcomes 
were also assessed.
Safety outcomes analyzed to assess the risks of upadaci-
tinib were serious infection, herpes zoster, malignancies 
excluding non-melanoma skin cancer (NMSC), MACE, 
and VTE. These represent labeled warnings for upadaci-
tinib and other JAK inhibitors that are potentially serious or 
life threatening and can result in severe outcomes such as 
hospitalization or death.
4.2  Upadacitinib Benefit–Risk Analysis Up 
to Regulatory Submission
Three integrated analyses of upadacitinib 15 mg once daily 
versus placebo, methotrexate, and adalimumab 40 mg EOW 
were conducted based on phase III data up to regulatory 
submission. The placebo-controlled analysis set (upadaci-
tinib 15 mg vs. placebo, both with background methotrexate/
csDMARDs) was based on short-term (week 12/14) data 
from SELECT-BEYOND, SELECT-NEXT, and SELECT-
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0.10 0.05 0.00 01.0 –50.0 –
Difference in proportion through week 12c or week 14d (95% CI)
(A) Benefita
(B) Riskb
Favors PBO Favors UPA 15 mga
PBO-controlled UPA 15 mg analysis set: UPA VS. PBO
(SELECT-BEYOND, SELECT-NEXT, and SELECT-COMPARE)
Favors PBO Favors UPA 15 mgb
Fig. 1  Integrated analysis of the a benefits and b risks of upadaci-
tinib 15 mg once daily compared with placebo with background 
csDMARDs/MTX in csDMARD/MTX-IR and bDMARD-IR 
patients. aA positive value indicates more favorable efficacy with 
upadacitinib 15 mg than with placebo. bA negative value indicates 
more favorable safety with upadacitinib 15 mg than with placebo. 
cSELECT-BEYOND and SELECT-NEXT. dSELECT-COMPARE. 
ACR20/50/70 20/50/70% improvement in American College of Rheu-
matology criteria, bDMARD biologic disease-modifying antirheu-
matic drug, BL baseline, CDAI Clinical Disease Activity Index, CI 
confidence interval, CR clinical remission, csDMARD conventional 
synthetic disease-modifying antirheumatic drug, DAS28(CRP) Dis-
ease Activity Score of 28 joints with C-reactive protein, excl. exclud-
ing, HAQ-DI Health Assessment Questionnaire-Disability Index, IR 
inadequate responder, LDA low disease activity, MACE major adverse 
cardiovascular event, MTX methotrexate, NMSC non-melanoma skin 
cancer, PBO placebo, UPA upadacitinib, VTE venous thromboem-
bolic event
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analysis set compared upadacitinib 15 mg monotherapy 
with methotrexate monotherapy in methotrexate-naïve 
and methotrexate-IR patients using week 12/14 efficacy 
data and week 24/14 safety data from SELECT-EARLY/
SELECT-MONOTHERAPY, respectively. A comparison of 
upadacitinib 15 mg + methotrexate versus adalimumab + 
methotrexate was conducted using short-term (week 12/14) 
and long-term (week 48) data from SELECT-COMPARE 
(adalimumab-controlled upadacitinib 15 mg analysis set).
The differences between the proportion of patients 
achieving efficacy outcomes and experiencing safety events 
with the pooled upadacitinib 15 mg versus comparator 
analysis sets were calculated: (proportion of patients treated 
with upadacitinib 15 mg reporting outcome) − (propor-
tion of patients treated with comparator group reporting 
outcome). In the risk analysis comparing upadacitinib 15 
mg with adalimumab in methotrexate-IR patients, the differ-
ences between the events per 100 patient-years (E/100PY) of 
AEs were used instead of the incidence of AEs. Ninety-five 
percent confidence intervals (CIs) were calculated based on 
Mantel–Haenszel estimation and adjusted for the study as a 
stratification factor.
Overall, a positive value indicates that a greater pro-
portion of patients treated with upadacitinib reported the 
outcome of interest. Therefore, when considering benefits, 
positive values indicate that upadacitinib 15 mg is more 
favorable than its comparators. However, when considering 
risks, negative values indicate that upadacitinib 15 mg is 
more favorable than its comparators.
DAS28(CRP) < 2.6
HAQ-DI change from BL ≤ – 0.22
Difference in proportion (95% CI)
Difference in E/100PY (95% CI)
(A) Benefitc
(B) Riskd
ADA-controlled UPA 15 mg analysis set:














10.0 5.0 0.00 0.01–0.5–
gm51APUsrovaFADAsrovaF d
Short-terma Long-termb
Fig. 2  Integrated analysis of the a benefits and b risks of upadaci-
tinib 15 mg once daily + MTX compared with adalimumab + MTX 
in MTX-IR patients. aShort term efficacy is measured at week 12 
and short term safety is measured through week 14. bLong term effi-
cacy and safety are measured at/through week 48. Long term safety 
is based on any UPA 15 mg once daily and any adalimumab 40 mg 
EOW patient populations. cA positive value indicates more favorable 
efficacy with upadacitinib 15 mg than with adalimumab. dA negative 
value indicates more favorable safety with upadacitinib 15 mg than 
with adalimumab. ACR20/50/70 20/50/70% improvement in Ameri-
can College of Rheumatology criteria, ADA adalimumab, BL base-
line, CDAI Clinical Disease Activity Index, CI confidence interval, 
CR clinical remission, DAS28(CRP) Disease Activity Score of 28 
joints with C-reactive protein, E/100PY events per 100 patient-years, 
EOW every other week, excl. excluding, HAQ-DI Health Assessment 
Questionnaire-Disability Index, IR inadequate responder, LDA low 
disease activity, MACE major adverse cardiovascular event, MTX 
methotrexate, NMSC non-melanoma skin cancer, UPA upadacitinib, 
VTE venous thromboembolic event
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4.3  Long‑Term Integrated Safety Analysis 
of Upadacitinib
An integrated safety assessment with long-term follow-up 
across the five pivotal SELECT phase III studies has been 
previously described [43–47]. Here, we reviewed these 
data up to the cut-off date of June 30, 2019 for pooled upa-
dacitinib 15 mg (five trials; median exposure 101.9 weeks), 
methotrexate (one trial; median exposure 92.6 weeks), and 
adalimumab (one trial; median exposure 78.6 weeks). AEs 
of special interest were reported as exposure-adjusted event 
rates (EAERs) defined as the total number of E/100PY, 
including multiple events that occurred in the same patient.
5  Benefit Assessment
5.1  Improvement of Disease Status
Upadacitinib 15 mg + background csDMARDs/methotrex-
ate in patients who were either csDMARD/methotrexate-
IR or bDMARD-IR was superior to placebo at week 12 
across composite indices for measures of clinical response 
and overall disease status (SELECT-NEXT, SELECT-
COMPARE, and SELECT-BEYOND) (Fig. 1 and Table 1 
[25, 48, 49]). Compared with placebo, significantly higher 
proportions of patients achieved ACR responses (with the 
exception of ACR70 at week 12 in SELECT-BEYOND) as 
well as remission and LDA by all definitions. Responses 
improved through week 48 and continued through week 60 
(SELECT-NEXT and SELECT-BEYOND [50, 51]).
In a direct head-to-head comparison with adali-
mumab + methotrexate in methotrexate-IR patients 
(A) Benefitc
(B) Riskd
MTX controlled UPA 15 mg monotherapy analysis set:
UPA + MTX (SELECT-EARLY and SELECT-MONOTHERAPY)
Difference in proportion through week 24a or week 14b (95% CI)
















0.10 0.05 0.00 01.0–50.0–
gm51APUsrovaFXTMsrovaF d
MTX-naïvea MTX-IRb
Fig. 3  Integrated analysis of the a benefits and b risks of upadaci-
tinib 15 mg once daily as monotherapy compared with cMTX/MTX 
in MTX-IR and MTX-naïve patients. aSELECT-EARLY. bSELECT-
MONOTHERAPY. cA positive value indicates more favorable effi-
cacy with upadacitinib 15 mg than with MTX. dA negative value 
indicates more favorable safety with upadacitinib 15 mg than with 
MTX. ACR20/50/70 20/50/70% improvement in American College 
of Rheumatology criteria, BL baseline, CDAI Clinical Disease Activ-
ity Index, CI confidence interval, cMTX continuing methotrexate, CR 
clinical remission, DAS28(CRP) Disease Activity Score of 28 joints 
with C-reactive protein, excl. excluding, HAQ-DI Health Assess-
ment Questionnaire-Disability Index, IR inadequate responder, LDA 
low disease activity, MACE major adverse cardiovascular event, MTX 
methotrexate, NMSC non-melanoma skin cancer, UPA upadacitinib, 
VTE venous thromboembolic event
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Fig. 4  Event rates for TEAEs of special interest for upadacitinib 15 
mg once daily and active comparators (adapted from Cohen et  al. 
[44])a. MTX pooled: n = 314, PY = 456.0, median exposure = 92.6 
weeks; ADA 40 mg EOW: n = 579, PY = 768.6, median exposure 
= 78.6 weeks; UPA 15 mg pooled: n = 2629, PY = 4565.8, median 
exposure = 101.9 weeks. aPatients who switched from PBO, ADA, or 
MTX to UPA were included in the UPA analysis set from the start of 
UPA, whereas those who switched from UPA to ADA were included 
in the ADA dataset from the start of ADA. bMost herpes zoster cases 
were non-serious (95%) and involved a single dermatome (71%). 
cMACE was defined as CV death, non-fatal MI, and non-fatal stroke. 
dVTE was defined as DVT and PE. ADA adalimumab, CI confidence 
interval, CPK creatine phosphokinase, CV cardiovascular, DVT deep 
vein thrombosis, E/100PY events per 100 patient-years, EOW every 
other week, excl. excluding, MACE major adverse CV event, MI myo-
cardial infarction, MTX methotrexate, NMSC non-melanoma skin 
cancer, PE pulmonary embolism, TB tuberculosis, TEAE treatment-
emergent adverse event, UPA upadacitinib, VTE venous thromboem-
bolic event
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(SELECT-COMPARE), upadacitinib + methotrexate dem-
onstrated superior efficacy based on ACR50 at week 12, 
which was maintained to week 48 [25, 52]. Significantly 
greater proportions of patients treated with upadacitinib 
also achieved ACR20/ACR70 responses, DAS28(CRP) < 
2.6, CDAI remission, and Boolean remission compared with 
those treated with adalimumab at week 12, which were also 
maintained at weeks 24 and 48 [25, 52] (Fig. 2).
Upadacitinib monotherapy was superior to methotrexate 
at week 12 or 14, respectively, across multiple measures of 
clinical response and disease states, in patients who were 
methotrexate-naïve (SELECT-EARLY) or methotrexate-IR 
(SELECT-MONOTHERAPY) [29, 53] (Fig. 3, Table 1). 
This was maintained to week 48 in both studies [54, 55].
Of note, upadacitinib as combination therapy or mono-
therapy demonstrated a rapid onset of action, with statisti-
cally significant responses as early as week 2 compared with 
placebo or methotrexate, respectively.
5.2  Inhibition of Progression of Structural Joint 
Damage
According to EULAR recommendations, treatment deci-
sions should be based on progression of structural damage 
in addition to disease activity and safety, with the inhibition 
of structural damage highlighted as an important differentia-
tor of DMARDs from strictly symptomatic antirheumatic 
agents, such as non-steroidal anti-inflammatory drugs [6].
In the upadacitinib development program, radiographic 
progression was assessed in both methotrexate-naïve and 
methotrexate-IR populations (SELECT-EARLY and 
SELECT-COMPARE). Upadacitinib + methotrexate in 
methotrexate-IR patients showed a statistically significant 
reduction in the progression of structural joint damage com-
pared with placebo + methotrexate at week 26, with a signif-
icantly greater proportion of patients having no radiographic 
progression [25]. Inhibition of structural joint damage was 
maintained through week 48 [52]. Similarly, upadacitinib 
monotherapy in methotrexate-naïve patients showed a statis-
tically significant reduction in the progression of structural 
joint damage compared with methotrexate monotherapy, as 
well as a significantly greater percentage of patients with no 
radiographic progression at week 24 (Table 1 and van Vol-
lenhoven et al. [29]), with inhibition of progression main-
tained through week 48 [55].
5.3  Improved Function
Upadacitinib + background csDMARDs/methotrexate was 
superior to placebo at week 12 for both improvement in 
HAQ-DI and for the percentage of patients achieving MCID 
in HAQ-DI (reduction from baseline ≥ 0.22) (Fig. 1; Table 2 
in the ESM). Upadacitinib + methotrexate demonstrated 
superior improvement in HAQ-DI compared with adali-
mumab + methotrexate at week 12, with significant differ-
ences from week 8 that were maintained through week 48 
[25, 52] (Fig. 2). The percentage of patients receiving upa-
dacitinib + methotrexate who achieved MCID for HAQ-DI 
in the upadacitinib group was significantly greater than that 
of those receiving adalimumab + methotrexate at week 48.
Similar to combination therapy with csDMARDs, upa-
dacitinib monotherapy was superior to methotrexate at week 
12 or 14 for both improvement in HAQ-DI and for the per-
centage of patients achieving the MCID (Fig. 3; Table 2 in 
the ESM). These responses were maintained through week 
48.
5.4  Additional Patient‑Reported Outcomes
Other patient-reported outcomes included morning stiff-
ness duration, health-related QoL (Short Form-36 physical 
component summary), fatigue (Functional Assessment of 
Chronic Illness Therapy-Fatigue), and pain. Upadacitinib 15 
mg with or without background csDMARDs/methotrexate 
showed statistically significant improvements across all of 
these outcome measures in patients who were methotrex-
ate-naïve, csDMARD-IR/methotrexate-IR, or bDMARD-IR 
(fatigue and pain were not assessed in patients who were 
bDMARD-IR or csDMARD-IR, respectively) compared 
with the placebo and active comparator groups (Table 2 in 
the ESM). Of note, improvement of pain with upadacitinib 
+ methotrexate was superior to adalimumab + methotrexate 
at week 12 and was maintained to week 48 in SELECT-
COMPARE [25, 52].
6  Risk Assessment
In this review, risks associated with upadacitinib were 
assessed using short-term integrated risk analyses based 
on phase III clinical data (week 12 for SELECT-BEYOND, 
SELECT-NEXT, and SELECT-EARLY; week 14 for 
SELECT-MONOTHERAPY; and weeks 14/48 for SELECT-
COMPARE; Figs. 1, 2 and 3) and a long-term integrated 
safety analysis (Fig. 4), which included 2629 patients who 
received at least one dose of upadacitinib 15 mg (4565.8 
patient-years (PY); median exposure: 101.9 weeks), 314 
patients who received methotrexate (456.0 PY; median 
exposure: 92.6 weeks), and 579 patients who received adali-
mumab (768.6 PY; median exposure: 78.6 weeks).
A detailed description of the integrated safety profile 
of upadacitinib 15 mg from an earlier data cut (2655 PY; 
median exposure: 53.6 weeks) has been previously reported 
[43]. Cox regression analyses from this report suggested 
that upadacitinib 15 mg treatment was associated with an 
increased risk of herpes zoster and CPK elevations compared 
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with placebo, methotrexate, and adalimumab. A summary of 
TEAEs and laboratory abnormalities observed with upadaci-
tinib 15 mg and its comparators was also described.
6.1  Serious Infections
In the short-term risk analyses, numerically greater propor-
tions of patients treated with upadacitinib 15 mg experienced 
serious infections compared with placebo in combination 
with background csDMARDs (Fig. 1), but similar propor-
tions of patients receiving upadacitinib 15 mg and metho-
trexate monotherapy reported serious infections (Fig. 3). 
In the SELET-COMPARE study, numerically higher rates 
of serious infections with upadacitinib 15 mg versus adali-
mumab were also observed at week 14 but not at week 48 
(Fig. 2).
In the long-term integrated analysis, the EAER of serious 
infection among any patient receiving upadacitinib 15 mg 
across all five phase III studies was 3.2 E/100PY (95% CI 
2.7–3.7 [46]; Fig. 4). This was consistent with that observed 
in patients treated with adalimumab (3.9 E/100PY [95% CI 
2.6–5.6]) and methotrexate (3.1 E/100PY [95% CI 1.7–5.2]). 
Comparisons of rates or incidence of events across differ-
ent clinical programs conducted in different patient popula-
tions should be interpreted with caution; however, the EAER 
of serious infection reported with upadacitinib 15 mg was 
within the range reported for the RA clinical development 
programs of tofacitinib, tocilizumab, and sarilumab [56–58]. 
According to Cox regression analyses from an earlier data 
cut, upadacitinib 15 mg was not associated with higher risk 
of serious infections compared with adalimumab (hazard 
ratio 0.8 [95% CI 0.5–1.4]) or methotrexate (hazard ratio 1.6 
[95% CI 0.7–3.4]) [43]. The EAER of upadacitinib 15 mg 
did not increase over time. The types of serious infections 
reported in patients treated with upadacitinib were generally 
consistent with those anticipated in patients with RA, with 
pneumonia being most common. Among patients receiv-
ing upadacitinib 15 mg, those who were aged ≥ 75 years 
and smoked, but not those who were receiving concomitant 
methotrexate or glucocorticoids, had an increased risk of 
serious infections [46].
Opportunistic infections in patients treated with upadaci-
tinib 15 mg were reported at a rate of 0.7 E/100PY (95% 
CI 0.5–1.0) and were comparable with those observed in 
patients treated with adalimumab (Fig. 4). The majority of 
opportunistic infections were non-serious oral candidiasis 
[46]. Rates of latent/active tuberculosis were similar across 
upadacitinib 15 mg, methotrexate, and adalimumab.
6.2  Herpes Zoster
Herpes zoster was more commonly observed with upadaci-
tinib 15 mg than comparators across phase III studies in 
the short term (Figs. 1, 2 and 3). A total of 142 patients 
receiving upadacitinib 15 mg with an EAER of 3.4 E/100PY 
(95% CI 2.9–4.0) experienced herpes zoster across the five 
pivotal phase III trials with up to 3 years of follow-up [44, 
45] (Fig. 4). The rate of herpes zoster was higher in patients 
treated with upadacitinib than in those receiving placebo, 
methotrexate, or adalimumab. In patients who received 
upadacitinib 15 mg, the majority of herpes zoster events 
involved a single dermatome (71%) and were non-serious 
(95%). Seven events of disseminated herpes zoster, six 
events of ophthalmic herpes zoster (periorbital involvement), 
and six events of post-herpetic neuralgia were reported in 
patients receiving upadacitinib 15 mg. No patient experi-
enced central nervous system involvement in the 15 mg 
group.
Using multivariate analysis, prior herpes zoster and age ≥ 
65 years were identified as risk factors for the development 
of herpes zoster while receiving upadacitinib 15 mg, and 
a higher rate of herpes zoster was seen in the Asian region 
than in other geographic regions (Table 3 in the ESM), as 
observed with other JAK inhibitors [59, 60]. Within Asia, 
the highest rate of herpes zoster was observed in Japan (12.2 
E/100PY [95% CI 7.0–19.9]), and the increased risk of her-
pes zoster in the Japanese versus global populations treated 
with upadacitinib 15 mg has been previously reported [61, 
62]. There was no apparent association between the use of 
methotrexate and/or concomitant corticosteroids at baseline 
with the development of herpes zoster [45].
6.3  Malignancy
Upadacitinib 15 mg had similar rates of malignancy exclud-
ing NMSC compared with placebo, methotrexate, and adal-
imumab across patient populations in the short-term risk 
analyses (Figs. 1, 2 and 3). In the long-term analysis, the 
EAER for malignancy excluding NMSC in the upadacitinib 
15 mg group was 0.9 E/100PY (95% CI 0.6–1.2), which was 
comparable with adalimumab and methotrexate (Fig. 4). A 
standardized incidence ratio (SIR) analysis for malignancy 
excluding NMSC, adjusted for age and sex from the Sur-
veillance, Epidemiology, and End Results 18 Registry Data 
2000–2015 for the general population, yielded an SIR esti-
mate of 1.05 (95% CI 0.66–1.60) for the upadacitinib 15 
mg group in an earlier data cut [43], which suggests that 
the number of malignancies excluding NMSC in patients 
exposed to upadacitinib was not significantly higher than 
expected. As mentioned, comparisons between different 
clinical trial programs should be interpreted with cau-
tion; however, the EAER for malignancy excluding NMSC 
reported with upadacitinib 15 mg was within the range 
reported for the RA clinical development programs of tofaci-
tinib, baricitinib, tocilizumab, and sarilumab [56–58, 63].
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The types of malignancies observed reflected those 
expected in patients with moderately to severely active RA 
[64], and no notable pattern was observed for the types of 
malignancies reported. Rates of NMSC were similar across 
upadacitinib 15 mg, methotrexate, and adalimumab.
6.4  Major Adverse Cardiovascular Events
In the short-term risk analyses, similar rates of MACE were 
observed with upadacitinib and placebo, methotrexate, and 
adalimumab (Figs. 1, 2 and 3). In the long-term integrated 
analysis, the EAER for MACE in the upadacitinib 15 mg 
group was 0.5 E/100PY (95% CI 0.3–0.7) [44]. Rates of 
MACE were comparable between the upadacitinib, adali-
mumab, and methotrexate groups (Fig. 4). While compari-
sons between clinical trial programs should be interpreted 
with caution, the rate for MACE reported with upadacitinib 
15 mg was within the range of that reported for the clinical 
RA development programs of tofacitinib, baricitinib, and 
sarilumab [56, 58, 63]. The incidence rates for MACE did 
not increase over time, and there was no pattern in the time 
to onset for MACE. All patients who experienced MACE 
during upadacitinib therapy had at least one cardiovascular 
risk factor.
While reducing chronic inflammation with effective ther-
apies may reduce cardiovascular disease risk in patients with 
RA [65], JAK inhibitors, including upadacitinib, are also 
associated with an increase in serum lipid levels. Although 
treatment with upadacitinib led to increased levels of low-
density lipoprotein cholesterol (LDL-C) and high-density 
lipoprotein cholesterol, their ratio remained constant over 
time and there was no association between elevated LDL-C 
and the occurrence of MACE [66].
6.5  Venous Thromboembolic Events
Similar rates of VTEs were observed with upadacitinib 
15 mg and its comparators in the short-term risk analyses 
(Figs. 1, 2 and 3) and long-term integrated analysis (Fig. 4). 
The EAER for VTEs reported with upadacitinib 15 mg was 
0.5 E/100PY (95% CI 0.3–0.7), which was comparable with 
the rates with adalimumab or methotrexate (Fig. 4) and also 
similar to that observed in the general RA population (~ 
0.6 n/100PY) [67]. In total, 21 VTEs were observed in 20 
patients receiving upadacitinib 15 mg, of which 11 events 
were PE only, five events were DVT only, and four events 
were PE + DVT [47]. There was no pattern in the timing 
of VTEs in patients receiving upadacitinib 15 mg, and the 
accumulative probability of VTE in this treatment group 
over 3 years was ≤ 1%. All patients who experienced a VTE 
had at least one known risk factor. Subsequent analysis sug-
gested prior VTE, age ≥ 65 years, non-steroidal anti-inflam-
matory drug or statin use, and—to a lesser extent—higher 
body mass index (BMI), were risk factors for the develop-
ment of VTE in patients receiving upadacitinib 15 mg [47]. 
These factors are known to increase the risk of VTE in the 
general population [68].
6.6  Other Treatment‑Emergent Adverse Events 
of Special Interest
Similar to other JAK inhibitors [16, 17, 19, 32], treatment 
with upadacitinib has been associated with an increased inci-
dence of CPK elevations compared with placebo, methotrex-
ate, and adalimumab (Fig. 4). Most cases of CPK elevations 
were asymptomatic, and no cases of rhabdomyolysis were 
observed with upadacitinib 15 mg. CPK elevations > 5 × 
the upper limit of normal were transient and did not require 
treatment discontinuation, with mean CPK levels increasing 
through 12 weeks of treatment and remaining stable at an 
increased value thereafter.
Although a higher incidence of hepatic transaminase 
elevations was observed with upadacitinib 15 mg than with 
placebo during the short-term placebo-controlled period 
[18], similar rates of hepatic disorders (most of which were 
transaminase elevations) were observed across upadacitinib 
15 mg, methotrexate, and adalimumab in the long-term inte-
grated analysis (Fig. 4). Most cases of hepatic transaminase 
elevations with upadacitinib were asymptomatic and tran-
sient. If elevated hepatic transaminase levels are observed 
during routine patient management, and drug-induced liver 
injury is suspected, interruption of upadacitinib treatment is 
recommended until this diagnosis is excluded.
7  Benefit–Risk Evaluation
7.1  Summary of Benefits
Upadacitinib 15 mg in combination with background csD-
MARDs/methotrexate demonstrated superior efficacy based 
on clinical response and overall disease status, including 
achievement of LDA or remission and improvement in phys-
ical function compared with placebo at week 12 (Fig. 1). 
Similarly, upadacitinib 15 mg as monotherapy in methotrex-
ate-naïve or methotrexate-IR patients demonstrated superior 
efficacy across multiple disease outcome measures compared 
with methotrexate at week 12 (Fig. 3). Treatment with upa-
dacitinib 15 mg was associated with a rapid onset of action 
with statistically significant responses versus comparators 
as early as week 2. Upadacitinib demonstrated inhibition of 
structural joint damage both in combination with methotrex-
ate (in methotrexate-IR patients) and as monotherapy (in 
methotrexate-naïve patients) [25, 29, 52] (Table 1).
Upadacitinib also demonstrated superiority compared 
with two established biologic therapies. Upadacitinib had 
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significantly greater efficacy versus adalimumab in meth-
otrexate-IR patients, for all clinical (including remission) 
and patient-reported outcomes assessed in this analysis 
[25] (Fig. 2). Similarly, upadacitinib 15 mg demonstrated 
superior improvement in disease activity and remission com-
pared with abatacept in bDMARD-IR patients [38].
7.2  Summary of Risks
In the short-term placebo-controlled period, upadacitinib 15 
mg + csDMARDs had an increased incidence of serious 
infections and herpes zoster compared with placebo (Fig. 1). 
There was no notable difference in the incidence of MACE, 
malignancies, or VTEs between upadacitinib and pla-
cebo. With the exception of herpes zoster, all safety events 
reported in the short-term risk analyses occurred at a simi-
lar incidence with upadacitinib 15 mg monotherapy versus 
methotrexate (Fig. 3) or upadacitinib 15 mg + methotrexate 
versus adalimumab + methotrexate (Fig. 2). No new safety 
risks were observed in the long-term integrated safety analy-
sis of upadacitinib 15 mg, and—compared with methotrex-
ate or adalimumab—higher EAERs were only observed for 
herpes zoster and elevated CPK (Fig. 4). While not included 
in this integrated analysis, the safety profile of upadacitinib 
reported in SELECT-CHOICE was consistent with that from 
the five pivotal trials, with no new risks identified [38].
While the rate of VTEs with upadacitinib was similar to 
that with placebo and adalimumab, concerns around VTEs 
have been raised for other JAK inhibitors, which have led to 
cautionary use in certain patient populations [16]. In addi-
tion to pre-existing RA, all upadacitinib-treated patients who 
experienced VTEs had at least one known risk factor: prior 
VTE, age ≥ 65 years, non-steroidal anti-inflammatory drug 
or statin use, and high BMI [47]. Major surgery and pro-
longed immobilization are also listed as risk factors for VTE 
in the upadacitinib label [18]. Therefore, it is recommended 
that the risks and benefits be considered prior to initiating 
treatment with upadacitinib in patients who have known risk 
factors for VTE [18].
7.3  Summary of Benefit–Risk Assessment
Upadacitinib 15 mg, as monotherapy or in combination with 
csDMARDs/methotrexate, met all primary and ranked sec-
ondary efficacy endpoints and achieved significantly higher 
remission and LDA rates than placebo, methotrexate, and 
adalimumab across all five pivotal phase III trials in the 
SELECT clinical program [25, 29, 48, 49, 54].
Consistent with a previous integrated safety analysis 
[47], upadacitinib 15 mg was associated with higher rates 
of herpes zoster and CPK elevations but otherwise had a 
safety profile similar to that of methotrexate and adalimumab 
based on short- and long-term analyses. Risks observed with 
upadacitinib 15 mg were similar to those reported for other 
JAK inhibitors (tofacitinib and baricitinib) and other RA 
treatments (tocilizumab and sarilumab). No new safety risks 
were found with upadacitinib 15 mg compared with other 
JAK inhibitors.
An increased risk for herpes zoster was observed with 
upadacitinib 15 mg in this analysis. However, the numbers 
needed to treat (based on achieving CDAI remission) and 
the numbers needed to harm (based on an event of herpes 
zoster) compared with adalimumab over 26 weeks’ treat-
ment in SELECT-COMPARE were 11 and 216, respectively. 
This suggests that, for every additional case of herpes zos-
ter reported with upadacitinib over that reported with adali-
mumab, approximately 20 additional patients would achieve 
CDAI remission. The risk of herpes zoster is consistent with 
that observed with other JAK inhibitors, is familiar to health-
care professionals who treat patients with RA, and is consid-
ered manageable with standard clinical practice. However, 
the increased risk of herpes zoster observed in patients from 
Asia (particularly those in Japan), patients aged ≥65 years, 
and/or those with prior herpes zoster [45] should be consid-
ered by rheumatologists and discussed with patients prior to 
prescribing upadacitinib.
Increased rates of CPK elevations were also reported with 
upadacitinib compared with active comparators. CPK eleva-
tions reported with upadacitinib were mostly asymptomatic 
and transient and did not require treatment discontinuation. 
These elevations may be due to the restoration of myoblast 
differentiation mediated by JAK inhibition [69], and the cur-
rent consensus is that CPK testing is not required in patients 
receiving JAK inhibitors, including upadacitinib [70].
None of the covariates assessed (body weight, sex, race, 
ethnicity, age, renal/hepatic impairment) in the population 
pharmacokinetic analysis based on phase I–III clinical tri-
als had a clinically relevant effect on upadacitinib exposure 
[71, 72]. Therefore, the pharmacokinetics of upadacitinib 
are not expected to have a clinically meaningful effect on 
the efficacy or safety of upadacitinib. No dose adjustment is 
required in patients with mild or moderate renal or hepatic 
impairment [18].
The safety and efficacy of upadacitinib 15 mg was gener-
ally consistent with that of regional subpopulations, includ-
ing Central and Eastern European patients in a subgroup 
analysis of SELECT-COMPARE [73], Japanese patients in 
the SELECT-SUNRISE study [39], and a subgroup analysis 
of SELECT-EARLY [74]; and in Chinese, Brazilian, and 
South Korean patients in an independent phase III study 
[75]. The only notable difference was a higher incidence of 
herpes zoster in Japanese versus global patients [39, 74].
Overall, these data suggest that upadacitinib 15 mg has a 
favorable benefit–risk profile for the treatment of RA. How-
ever, rheumatologists should ensure any potential risks are 
communicated prior to prescribing upadacitinib to patients, 
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especially those who have relevant risk factors. As with all 
RA treatments, patients should also be monitored by a spe-
cialist while receiving upadacitinib.
7.4  Uncertainties Related to Benefits and Risks
Although the upadacitinib clinical development program 
was robust, uncertainties remain regarding the characteriza-
tion of risks of upadacitinib and its use in certain populations 
who were under-represented in clinical trials. For example, 
clinical trials exclude patients with significant underlying 
conditions in whom safety risks may be different. Uncertain-
ties also exist for risks requiring long-term observation to 
understand whether there is an association with upadacitinib 
use. Due to clinical trial exclusion criteria, there is limited 
exposure of upadacitinib in patients with severe renal or 
hepatic impairment and in patients aged ≥ 75 years, and upa-
dacitinib has not yet been evaluated in children and will not 
be indicated for use in pediatric patients aged < 18 years at 
this time. However, these are generic limitations associated 
with phase III clinical data, which may be rectified when 
long-term post-marketing data become available.
8  Planned/Ongoing Pharmacovigilance 
Activities
Long-term observation of the safety and efficacy of upadaci-
tinib will continue through ongoing long-term extensions for 
clinical trials and planned pharmacoepidemiologic studies. 
These include long-term database studies (in the USA and 
the EU), which will provide evidence in support of the safety 
profile of upadacitinib in real-world populations, especially 
those that were under-represented during clinical trials. Upa-
dacitinib studies in children with juvenile idiopathic arthritis 
are also planned.
9  Conclusions
Upadacitinib is an oral, once-daily selective JAK inhibitor 
that has been evaluated in a phase III clinical development 
program. With over 2600 patients and 4500 PY of exposure, 
upadacitinib 15 mg demonstrated a favorable benefit–risk 
profile, both in combination with csDMARDs/methotrexate 
or as a monotherapy across a range of patients with moder-
ately to severely active RA, including those who were naïve 
to methotrexate, and those who were IRs or had intolerance 
to csDMARDs or bDMARDs. Upadacitinib fills an unmet 
medical need for patients with RA, providing significantly 
greater rates of disease outcomes (remission and LDA) 
compared with established therapies (methotrexate, adali-
mumab, and abatacept), and inhibits structural joint damage. 
While labeled risks of upadacitinib include serious infection, 
herpes zoster, malignancies excluding NMSC, MACE, and 
VTE, with the exception of herpes zoster and CPK eleva-
tions, the safety profile of upadacitinib was similar to that 
observed with adalimumab.
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